

Amendments to the Claims:

This claim listing will replace all prior versions and listings of claims in the application:

Claim Listing:

- 1-19. (Cancelled)
20. (Currently Amended) An immunostimulatory oligonucleotide compound, comprising:

an immunostimulatory dinucleotide of formula CpG 5'-pyrimidine-purine-3', wherein
pyrimidine C is a natural or non-natural pyrimidine nucleoside and purine G is a natural
or non-natural purine nucleoside, and wherein p is an internucleotide linkage selected
from the group consisting of phosphodiester, phosphorothioate and phosphorodithioate;

a 3'-3' linkage; and

one or two accessible 5' ends;

provided that the oligonucleotide is not complementary to the *gag* or *tat* gene of HIV-1.
21. (Original) The immunostimulatory oligonucleotide compound of claim 20, which
oligonucleotide comprises two accessible 5' ends.
22. (Canceled)
- 23-38. (Cancelled)
39. (New) An immunostimulatory oligonucleotide compound, comprising:

an immunostimulatory dinucleotide of formula CpG, wherein C is a natural pyrimidine
nucleoside and G is a non-natural purine nucleoside, and wherein p is an internucleotide
linkage selected from the group consisting of phosphodiester, phosphorothioate and
phosphorodithioate;

a 3'-3' linkage; and

one or two accessible 5' ends;

provided that the oligonucleotide is not complementary to the *gag* or *tat* gene of HIV-1.

40. (New) The immunostimulatory oligonucleotide compound of claim 20, which oligonucleotide comprises two accessible 5' ends.